Comparison 21. Vitapex pulpectomy versus zinc oxide and eugenol (ZOE) pulpectomy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical failure	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 6 months	4	287	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.84]
1.2 12 months	4	287	Risk Ratio (M‐H, Fixed, 95% CI)	4.75 [1.21, 18.55]
2 Radiological failure	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 6 months	4	287	Risk Ratio (M‐H, Fixed, 95% CI)	2.36 [0.86, 6.50]
2.2 12 months	4	287	Risk Ratio (M‐H, Fixed, 95% CI)	6.56 [2.58, 16.67]
3 Overall failure	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 6 months	2	140	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [0.63, 5.66]
3.2 12 months	2	140	Risk Ratio (M‐H, Fixed, 95% CI)	2.56 [0.89, 7.32]
4 Pain	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 6 months	3	180	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 12 months	3	180	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Pathological mobility	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 6 months	3	180	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.84]
5.2 12 months	3	180	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 15.18]